Currently underway is the open-label phase 3 trial LIBRETTO-431, comparing the efficacy of selpercatinib to that of standard chemotherapy (cisplatin/carboplatin + pemetrexed) in combination with pembrolizumab in patients with RET-positive NSCLC [74]. This evidence concerns the gene RET and non-small cell lung carcinoma.